These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34042040)

  • 1. Immunotherapies for Parkinson's Disease: Progression of Clinical Development.
    Teng JS; Ooi YY; Chye SM; Ling APK; Koh RY
    CNS Neurol Disord Drug Targets; 2021; 20(9):802-813. PubMed ID: 34042040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
    Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
    Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease.
    Béné R; Antić S; Budisić M; Lisak M; Trkanjec Z; Demarin V; Podobnik-Sarkanji S
    Acta Clin Croat; 2009 Sep; 48(3):377-80. PubMed ID: 20055267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The understanding of Parkinson's disease through genetics and new therapies.
    Uwishema O; Onyeaka H; Badri R; Yücel AN; Korkusuz AK; Ajagbe AO; Abuleil A; Chaaya C; Alhendawi BHM; Chalhoub E
    Brain Behav; 2022 May; 12(5):e2577. PubMed ID: 35451243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the Mechanisms of Antibody Binding to Alpha-Synuclein for the Treatment of Parkinson's Disease.
    Harrison MC; Lai PK
    Mol Pharm; 2024 Oct; 21(10):5326-5334. PubMed ID: 39251364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
    Castonguay AM; Gravel C; Lévesque M
    J Parkinsons Dis; 2021; 11(1):71-92. PubMed ID: 33104039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.
    Weihofen A; Liu Y; Arndt JW; Huy C; Quan C; Smith BA; Baeriswyl JL; Cavegn N; Senn L; Su L; Marsh G; Auluck PK; Montrasio F; Nitsch RM; Hirst WD; Cedarbaum JM; Pepinsky RB; Grimm J; Weinreb PH
    Neurobiol Dis; 2019 Apr; 124():276-288. PubMed ID: 30381260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
    Galiano-Landeira J; Torra A; Vila M; Bové J
    Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Premotor diagnosis of Parkinson's disease].
    Morales-Briceño H; Cervantes-Arriaga A; Rodríguez-Violante M
    Gac Med Mex; 2011; 147(1):22-32. PubMed ID: 21412393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of Parkinson's disease.
    Lew M
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):155S-160S. PubMed ID: 18041935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
    Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
    Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in Parkinson's disease: Current status and future directions.
    Chatterjee D; Kordower JH
    Neurobiol Dis; 2019 Dec; 132():104587. PubMed ID: 31454546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
    Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.
    Schofield DJ; Irving L; Calo L; Bogstedt A; Rees G; Nuccitelli A; Narwal R; Petrone M; Roberts J; Brown L; Cusdin F; Dosanjh B; Lloyd C; Dobson C; Gurrell I; Fraser G; McFarlane M; Rockenstein E; Spencer B; Masliah E; Spillantini MG; Tan K; Billinton A; Vaughan T; Chessell I; Perkinton MS
    Neurobiol Dis; 2019 Dec; 132():104582. PubMed ID: 31445162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.